Features that make a difference

AccuLiftTM Laser Capture Microdissection System

frontView
sideView
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
View more
Zoom in
View workflow
Loader

A simple, streamlined workflow

With LCM instrument, consumables and extraction reagent kits

  • 1Preparation
  • 2Selection
  • 3Purification
  • 4Molecular analysis
  • Preparation

The AccuLift LCM Release Slides improves tissue recovery with each laser pulse, even for challenging samples like frozen and FFPE tissue.

Products:

AccuLift LCM Digital Pathology Solution

Create regions of interest remotely and collaborate in the cloud

Slide Digitalization

Slide Digitalization

Whole slide scanning of frozen and formalin-fixed, paraffin-embedded tissue sections

Cloud Pathology

Cloud Pathology

Case reviews, annotations and collaborations on high-quality cellular regions of interest

Laser Capture Microdissection

Laser Capture Microdissection

Cancer, immuno-oncology, neurological and immune-mediated diseases

Applications

Accurate, cell-specific data for a variety of downstream applications

  • ONCOLOGY

    ONCOLOGY

    Study specific tumor and nontumor cells within heterogeneous tumor microenvironment.

  • NEUROSCIENCE

    NEUROSCIENCE

    Analyze the thousands of cell types within heterogeneous central nervous system.

  • SINGLE CELLS

    SINGLE CELLS

    Microdissect single cells based on morphology, spatial biology or in situ biomarkers.

  • PROTEOMICS

    PROTEOMICS

    Spatially resolved and cell-specific proteomic analysis by mass spectrometry.

  • GENOMICS

    GENOMICS

    Profile the genome and transcriptome by next-generation sequencing or qPCR.

See how AccuLift is used

Advancing digital pathology and precision medicine

The need for LCM keeps growing and growing, and LCM and digital pathology — that is the future.

Lance Liotta, MD, PhD

Co-Director and Co-Founder of the Center for Applied
Proteomics and Molecular Medicine, George Mason University

Former Chief of the Laboratory of Pathology at the National
Cancer Institute and former Deputy Director at National
Institutes of Health

These new caps, having a higher efficiency, will help in that arena because we will have to microdissect less tissue per sample than we currently microdissect due to better efficiency.

Virginia (Ginny) Espina, PhD, MT (ASCP)

Center for Applied Proteomics and Molecular Medicine,
George Mason University

This next-generation LCM portfolio really addresses a problem that we face a lot in the lab, which is that you don’t have unlimited tissue supply. You have to get your extraction right the first time, or you may not have enough tissue to repeat that analysis.

Amanda Haymond, PhD

Center for Applied Proteomics and Molecular Medicine,
George Mason University